26833-87-4 | Homoharringtonine

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$74.00	$52.00
10mg	98%	in stock	$128.00	$90.00
25mg	98%	in stock	$229.00	$161.00
50mg	98%	in stock	$431.00	$302.00

Description

• Catalog Number: AD18459
• Chemical Name: Homoharringtonine
• CAS Number: 26833-87-4
• Molecular Formula: C29H39NO9
• Molecular Weight: 545.6213
• MDL Number: MFCD05618221
• SMILES: COC(=O)CC(C(=O)OC1C(=CC23C1c1cc4OCOc4cc1CCN3CCC2)OC)(CCCC(O)(C)C)O
• NSC Number: 141633

Computed Properties

• Complexity: 968
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 39
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 11
• XLogP3: 0.8

Literature

• [Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20130601

• [Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20130201

• Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.

  Annals of hematology 20121001

• [Cytotoxicity of homoharringtonine on leukemic stem-like cells in AML cell line KG-1].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20120901

• Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.

  Leukemia 20120601

• [Establishment of human homoharringtonine-resistant SKM-1 cell line and its biological characteristics].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20120601

• Investigation into omacetaxine solution stability for in vitro study.

  Biomedical chromatography : BMC 20120501

• Effect of homoharringtonine on bone marrow CD34 + CD117 + cells in patients with chronic myelogenous leukemia.

  Leukemia & lymphoma 20120501

• Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.

  British journal of haematology 20120501

• High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.

  Medical oncology (Northwood, London, England) 20120301

• Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival.

  Cancer research 20120201

• [Effects of interferon-α combined with homoharringtonine on K562 cell proliferation and β-catenin expression].

  Zhongguo shi yan xue ye xue za zhi 20120201

• Salvage therapy with endostatin, low-dose homoharringtonine, and cytarabine in combination with granulocyte-colony stimulating factor for elderly patients with primary refractory acute myeloid leukemia.

  American journal of hematology 20120101

• Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines.

  BMC medical genomics 20120101

• [Outcome of acute promyelocytic leukemia with homoharringtonine (HHT) and ATRA].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20111101

• Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.

  Journal of cancer research and clinical oncology 20111001

• Omacetaxine mepesuccinate for the treatment of leukemia.

  Expert opinion on pharmacotherapy 20111001

• [Effect of homoharringtonine combined with AG490 on JAK2-STAT5 associated signal pathway in HEL cells].

  Zhongguo shi yan xue ye xue za zhi 20111001

• [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].

  Zhongguo shi yan xue ye xue za zhi 20111001

• Successful treatment of childhood Philadelphia chromosome-positive acute myeloid leukemia.

  Pediatrics international : official journal of the Japan Pediatric Society 20110801

• Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.

  Journal of cancer research and clinical oncology 20110601

• Bcl-xL is a dominant antiapoptotic protein that inhibits homoharringtonine-induced apoptosis in leukemia cells.

  Molecular pharmacology 20110601

• Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells.

  Leukemia 20110601

• Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.

  International journal of hematology 20110501

• Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.

  Blood 20110106

• Omacetaxine as an anticancer therapeutic: what is old is new again.

  Current pharmaceutical design 20110101

• Omacetaxine: the FDA decision.

  Clinical advances in hematology & oncology : H&O 20110101

• [The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia].

  Zhonghua nei ke za zhi 20110101

• Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.

  Annals of hematology 20101101

• Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance.

  Cancer letters 20101001

• The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.

  Clinical lymphoma, myeloma & leukemia 20101001

• Retrospective robustness of the continual reassessment method.

  Journal of biopharmaceutical statistics 20100901

• Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS.

  Blood 20100506

• [Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism].

  Zhongguo shi yan xue ye xue za zhi 20100201

• Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.

  Anti-cancer agents in medicinal chemistry 20100201

• Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.

  Chinese medical journal 20100105

• The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.

  Molecular cancer therapeutics 20100101

• Novel screening method for potential skin-whitening compounds by a luciferase reporter assay.

  Bioscience, biotechnology, and biochemistry 20100101

• Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.

  Cancer 20091201

• Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines.

  Acta pharmacologica Sinica 20091101

• The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy.

  Leukemia & lymphoma 20091101

• Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.

  Leukemia & lymphoma 20090901

• Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.

  Leukemia 20090801

• Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.

  Chinese medical journal 20090620

• [Changes of gene expression profile in homoharringtonine-induced leukemia multi-drug resistant cell line K562/HHT].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20090601

• U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome.

  Journal of molecular biology 20090529

• A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.

  Cancer chemotherapy and pharmacology 20090401

• Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.

  American journal of hematology 20090401

• [Expression and function of Ahi-1 gene in Jurkat cells].

  Zhongguo shi yan xue ye xue za zhi 20090401

• [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].

  Zhongguo shi yan xue ye xue za zhi 20090401

• Separation and detection of isoquinoline alkaloids using MEEKC coupled with field-amplified sample injection induced by ACN.

  Electrophoresis 20090201

• [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20090101

• Altering chemosensitivity by modulating translation elongation.

  PloS one 20090101

• A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.

  Journal of hematology & oncology 20090101

• Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.

  European journal of haematology 20081001

• Synthesis of unsymmetrical biphenyls as potent cytotoxic agents.

  Bioorganic & medicinal chemistry letters 20081001

• [Efficiency of GHA priming chemotherapy on patients with refractory acute myeloid leukemia and myelodysplastic syndrome and its relationship with expression of costimulatory molecule B7.1].

  Zhongguo shi yan xue ye xue za zhi 20081001

• Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

  Leukemia & lymphoma 20081001

• [Effects of RNA interference targeting hypoxia-inducible factor-1alpha (HIF-1alpha) on chemosensitivity of leukemia K562 cells towards homoharringtonine].

  Ai zheng = Aizheng = Chinese journal of cancer 20080701

• Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin.

  International journal of hematology 20080601

• New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

  Expert opinion on investigational drugs 20080601

• Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.

  IDrugs : the investigational drugs journal 20080501

• Homoharringtonine for the treatment of chronic myelogenous leukemia.

  Expert opinion on pharmacotherapy 20080401

• The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia.

  American journal of hematology 20080301

• Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.

  American journal of hematology 20080301

• Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.

  Leukemia & lymphoma 20080301

• ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.

  British journal of haematology 20080101

• [HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20080101

• Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.

  Hematology. American Society of Hematology. Education Program 20080101

• Refractory multiple myeloma treated with homoharringtonine: report of two cases.

  Annals of hematology 20071201

• Gene expression profiling in apoptotic k562 cells treated by homoharringtonine.

  Acta biochimica et biophysica Sinica 20071201

• BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?

  Leukemia 20071001

• Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.

  Blood 20071001

• Chronic myeloid leukaemia in India.

  Lancet (London, England) 20070929

• TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade.

  FEBS letters 20070807

• Homoharringtonine induces apoptosis and growth arrest in human myeloma cells.

  Leukemia & lymphoma 20070701

• [Role of Bid protein in the mitochondria and Endoplasmic Reticulum associated apoptotic pathway].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20070701

• Effect of cantharidin, cephalotaxine and homoharringtonine on 'in vitro' models of hepatitis B virus (HBV) and bovine viral diarrhoea virus (BVDV) replication.

  Planta medica 20070601

• Gene expression pattern in apoptotic QGY-7703 cells induced by homoharringtonine.

  Acta pharmacologica Sinica 20070601

• Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway.

  Leukemia & lymphoma 20070501

• Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

  Cancer 20070115

• Recent developments in adaptive designs for Phase I/II dose-finding studies.

  Journal of biopharmaceutical statistics 20070101

• A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.

  British journal of cancer 20060807

• Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.

  Leukemia 20060801

• [Effect of several anti-tumor drugs on apoptosis induction in Jurkat cell line].

  Zhongguo shi yan xue ye xue za zhi 20060801

• Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.

  Anti-cancer drugs 20060701

• Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.

  International journal of oncology 20060501

• New strategies in chronic myeloid leukemia.

  International journal of hematology 20060501

• Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells.

  Molecular cancer therapeutics 20060301

• Homoharringtonine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of telomerase.

  The American journal of Chinese medicine 20060101

• Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.

  Cancer 20050501

• Correlation between survivin mRNA expression and homoharringtonine induced apoptosis of malignant hematopoietic cells.

  Chinese medical journal 20050405

• Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells.

  Chinese medical journal 20050320

• [Protection of mdr1 transfected cord blood mononuclear cell graft against anticancer agents in vivo].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20050201

• Effect of Homoharringtonine on corneal haze after excimer laser photorefractive keratectomy in rabbits.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20050101

• Homoharringtonine: a new treatment option for myeloid leukemia.

  Hematology (Amsterdam, Netherlands) 20040801

• Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP).

  American journal of hematology 20040701

• Investigational strategies in chronic myelogenous leukemia.

  Hematology/oncology clinics of North America 20040601

• Identification of genes responsive to apoptosis in HL-60 cells.

  Acta pharmacologica Sinica 20040301

• Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells.

  Journal of Zhejiang University. Science 20040201

• [Expression and significance of apoptosis protein inhibitor survivin and XIAP, in patients with myelodysplastic syndromes and in the cell line MUTZ-1].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20040101

• [Comparative proteomics research of apoptosis initiation induced by homoharringtonine in HL-60 cells].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20031201

• New agents in chronic myelogenous leukemia.

  Journal of the National Comprehensive Cancer Network : JNCCN 20031001

• Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.

  Cancer 20030901

• [Glivec in combination with HA regimen for treatment of 20 patients with Ph chromosome positive acute leukemia].

  Ai zheng = Aizheng = Chinese journal of cancer 20030801

• A homoharringtonine-based regimen for childhood acute myelogenous leukemia.

  Medical and pediatric oncology 20030701

• [Inhibition of activation of nuclear factor-kappaB enhanced apoptosis of leukemic cells induced by homoharringtonine].

  Zhonghua nei ke za zhi 20030501

• [Effect of homoharringtonine on expression of human telomerase reverse transcriptase mRNA in HL-60 cells].

  Zhongguo shi yan xue ye xue za zhi 20030401

• Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.

  Naunyn-Schmiedeberg's archives of pharmacology 20030101

• Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia.

  Journal of experimental therapeutics & oncology 20030101

• In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.

  Cancer 20020515

• Homoharringtonine effective in CML patients.

  The Lancet. Oncology 20020501

• Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.

  Cancer 20020401

• [Chemotherapy and radiation therapy].

  Nihon rinsho. Japanese journal of clinical medicine 20011201

• Homoharringtonine: history, current research, and future direction.

  Cancer 20010915

• A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study.

  Medical and pediatric oncology 20010801

• [Involvement of mitochondrial membrane potential in the homoharringtonine induced apoptosis of leukemic T-cells].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20010501

• In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.

  Blood 20010401

• Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation.

  Leukemia 20010401

• [Severe side effects of the treatment of acute promyelocytic leukemia with all-trans retinoic acid].

  Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University 20000628

• Homoharringtonine: an effective new natural product in cancer chemotherapy.

  Bulletin du cancer 19951201

• Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.

  Journal of natural products 19910101

• Inhibition of translation in eukaryotic systems by harringtonine.

  European journal of biochemistry 19770101

• Inhibition of protein synthesis in intact HeLa cells.

  Antimicrobial agents and chemotherapy 19751001